PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases
- 1 January 2021
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112949
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81573281 and 81973207)
This publication has 36 references indexed in Scilit:
- Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid Pathology and Restores Lysosomal Acidification and Mammalian Target of Rapamycin Activity in the Alzheimer Disease Mouse ModelJournal of Biological Chemistry, 2013
- GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrusHippocampus, 2011
- Does lithium protect against dementia?Bipolar Disorders, 2010
- TNF-α and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjectsJournal of Neuroimmunology, 2009
- GSK-3 is a master regulator of neural progenitor homeostasisNature Neuroscience, 2009
- α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease modelsThe FASEB Journal, 2009
- A High Throughput Luminescent Assay for Glycogen Synthase Kinase-3 β InhibitorsASSAY and Drug Development Technologies, 2007
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- GSK-3α regulates production of Alzheimer's disease amyloid-β peptidesNature, 2003
- Regulation of GSK-3Cell, 2001